Novel nonpeptidic inhibitors of HIV-1 protease obtained via a new multicomponent chemistry strategy.
Using a newly developed multicomponent chemistry strategy in combination with structure based drug design, a new class of HIV-1 protease inhibitors has been obtained.
Yehia
Nasser A M
NA
Morphochem AG, Gmunderstr--37-37a, 81379 München, Germany.
Antuch
Walfrido
W
Beck
Barbara
B
Hess
Sibylle
S
Schauer-Vukasinović
Vesna
V
Almstetter
Michael
M
Furer
Patrick
P
Herdtweck
Eberhardt
E
Dömling
Alexander
A
D001665:Binding Sites / Q000502:physiology; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D016333:HIV Protease / Q000378:metabolism*; D017320:HIV Protease Inhibitors / Q000138:chemical synthesis* / Q000378:metabolism* / Q000494:pharmacology
D017320:HIV Protease Inhibitors; D016333:HIV Protease